|
Jun 26
|
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Amid Chipmaker Optimism, Eyes Turn to Fed Leadership Speculation
|
|
Jun 26
|
Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma
|
|
Jun 9
|
June 2025's Spotlight On Promising Penny Stocks
|
|
May 29
|
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference
|
|
May 22
|
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX): When Will It Breakeven?
|
|
May 5
|
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission
|
|
May 5
|
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap
|
|
Apr 17
|
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors
|
|
Apr 11
|
3 Promising Penny Stocks With Market Caps Under $600M
|
|
Apr 3
|
Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter
|
|
Apr 3
|
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
|
|
Jan 20
|
Is Aldeyra Therapeutics (ALDX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?
|
|
Jan 1
|
3 US Penny Stocks With Market Caps Over $80M To Watch
|
|
Oct 3
|
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
|
|
Aug 9
|
Aldeyra’s Phase III clinical trial of Reproxalap meets primary endpoint
|
|
Aug 8
|
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
|
|
Aug 7
|
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
|
|
Jul 31
|
Owning 36% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX),
|
|
Jun 20
|
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
|
|
Jun 14
|
Aldeyra Therapeutics concludes subject enrolment in dry eye disease trial
|